The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Open accessAbstract
T-cell immunoglobulin mucin 3 (TIM3) is an inhibitory molecule that has emerged as a key regulator of dysfunctional or exhausted CD8+ T cells arising in chronic diseases such as cancer. In addition to exhausted CD8+ T cells, highly suppressive regulatory T cells (Tregs) represent a significant barrier against the induction of antitumor immunity. We have found that the majority of intratumoral FOXP3+ Tregs express TIM3. TIM3+ Tregs co-express PD-1, are highly suppressive and comprise a specialized subset of tissue Tregs that are rarely observed in the peripheral tissues or blood of tumor-bearing mice. The co-blockade of the TIM3 and PD-1 signaling pathways in vivo results in the downregulation of molecules associated with TIM3+ Treg suppressor functions. This suggests that the potent clinical efficacy of co-blocking TIM3 and PD-1 signal transduction cascades likely stems from the reversal of T-cell exhaustion combined with the inhibition of regulatory T-cell function in tumor tissues. Interestingly, we find that TIM3+ Tregs accumulate in the tumor tissue prior to the appearance of exhausted CD8+ T cells, and that the depletion of Tregs at this stage interferes with the development of the exhausted phenotype by CD8+ T cells. Collectively, our data indicate that TIM3 marks highly suppressive tissue-resident Tregs that play an important role in shaping the antitumor immune response in situ, increasing the value of TIM3-targeting therapeutic strategies against cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Self-citationThe Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Self-citationMonney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., et al. (2002) · Nature · doi:10.1038/415536a · Cited by 1,472
Self-citationRole of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Self-citationCooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858
Self-citationJones, R. B., Ndhlovu, L. C., Barbour, J. D., Sheth, P. M., Jha, A. R., Long, B. R., Wong, J. C., Satkunarajah, M., Schweneker, M., Chapman, J. M., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081398 · Cited by 753
Sánchez-Fueyo, A., Tian, J., Picarella, D., Domenig, C., Zheng, X. X., Sabatos, C. A., Manlongat, N., Bender, O., Kamradt, T., Kuchroo, V. K., et al. (2003) · Nature Immunology · doi:10.1038/ni987 · Cited by 712
Self-citationFoxp3 controls regulatory T-cell function by interacting with AML1/Runx1
Ono, M., Yaguchi, H., Ohkura, N., Kitabayashi, I., Nagamura, Y., Nomura, T., Miyachi, Y., Tsukada, T., & Sakaguchi, S. (2007) · Nature · doi:10.1038/nature05673 · Cited by 690
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Self-citationNgiow, S. F., von Scheidt, B., Akiba, H., Yagita, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 574
Self-citationSasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003) · Cancer · doi:10.1002/cncr.11618 · Cited by 484
Golden-Mason, L., Palmer, B. E., Kassam, N., Townshend-Bulson, L., Livingston, S., McMahon, B. J., Castelblanco, N., Kuchroo, V., Gretch, D. R., & Rosen, H. R. (2009) · Journal of Virology · doi:10.1128/jvi.00639-09 · Cited by 431
Self-citationGao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Wang, F., Sun, J., Yang, Q., Zhang, X., & Lu, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030676 · Cited by 407
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
Self-citationDysregulated T cell expression of TIM3 in multiple sclerosis
Koguchi, K., Anderson, D. E., Yang, L., O'Connor, K. C., Kuchroo, V. K., & Hafler, D. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060210 · Cited by 232
Self-citationIL-10, T cell exhaustion and viral persistence
Blackburn, S. D., & Wherry, E. J. (2007) · Trends in Microbiology · doi:10.1016/j.tim.2007.02.006 · Cited by 219
Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R., & Allison, J. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080099 · Cited by 218
Teng, M. W. L., Ngiow, S. F., von Scheidt, B., McLaughlin, N., Sparwasser, T., & Smyth, M. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1681 · Cited by 192
Self-citationTargeting Regulatory T Cells in Cancer
Byrne, W. L., Mills, K. H. G., Lederer, J. A., & O'Sullivan, G. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1156 · Cited by 189
Joosten, S. A., van Meijgaarden, K. E., Savage, N. D. L., de Boer, T., Triebel, F., van der Wal, A., de Heer, E., Klein, M. R., Geluk, A., & Ottenhoff, T. H. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702257104 · Cited by 185
Lack of TIM-3 Immunoregulation in Multiple Sclerosis
Yang, L., Anderson, D. E., Kuchroo, J. R., & Hafler, D. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4409 · Cited by 142
Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs
Gupta, S., Thornley, T. B., Gao, W., Larocca, R., Turka, L. A., Kuchroo, V. K., & Strom, T. B. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45138 · Cited by 139
Self-citationTakamura, S., Tsuji-Kawahara, S., Yagita∥, H., Akiba, H., Sakamoto, M., Chikaishi, T., Kato, M., & Miyazawa, M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903478 · Cited by 111
Tim-3 Pathway Controls Regulatory and Effector T Cell Balance during Hepatitis C Virus Infection
Moorman, J. P., Wang, J. M., Zhang, Y., Xiao, J., Cheng, J., Wu, X. Y., Jia, Z., Wang, K. S., & Yao, Z. Q. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200162 · Cited by 105
Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion
Teng, M. W. L., Swann, J. B., von Scheidt, B., Sharkey, J., Zerafa, N., McLaughlin, N. M., Yamaguchi, T., Sakaguchi, S., Darcy, P. K., & Smyth, M. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1574 · Cited by 84
Self-citationLippert, É., Yowe, D. L., Gonzalo, J.-Á., Justice, J. P., Webster, J. M., Fedyk, E. R., Hodge, M. R., Miller, C., Gutierrez-Ramos, J.-C., Borrego, F., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1542 · Cited by 80
The impact of regulatory T cells on carcinogen-induced sarcogenesis
Betts, G. J., Twohig, J. P., van den Broek, M. F., Sierro, S. R., Godkin, A. J., & Gallimore, A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603824 · Cited by 71
Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology
Teng, M. W. L., Ritchie, D. S., Neeson, P. J., & Smyth, M. J. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_50 · Cited by 37
Self-citation
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Self-citationKoyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
TIM3 comes of age as an inhibitory receptor
Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959
Self-citationCombination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Self-citation
Metadata
- Authors
- Sakuishi, K., Ngiow, S. F., Sullivan, J. M., Teng, M. W. L., Kuchroo, V. K., Smyth, M. J., & Anderson, A. C.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2013-04
- Volume
- 2
- Issue
- 4
- Pages
- e23849
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2151293773
- Cited by
- 328
- References
- 31
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.